Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical, Inc. (RARE)
NASDAQ:RARE
Total Valuation
Ultragenyx Pharmaceutical has a market cap or net worth of $1.97B. The enterprise value is $3.04B.
Market Cap$1.97B
Enterprise Value$3.04B
Share Statistics
Ultragenyx Pharmaceutical has 96,477,570 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding96,477,570
Owned by Insiders3.99%
Owned by Institutions4.23%
Financial Efficiency
Ultragenyx Pharmaceutical’s return on equity (ROE) is 7.19 and return on invested capital (ROIC) is -43.53%.
Return on Equity (ROE)7.19
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-43.53%
Return on Capital Employed (ROCE)-0.47
Revenue Per Employee520.09K
Profits Per Employee-444.36K
Employee Count1,294
Asset Turnover0.44
Inventory Turnover2.10
Valuation Ratios
The current PE Ratio of Ultragenyx Pharmaceutical is ―. Ultragenyx Pharmaceutical’s PEG ratio is 0.54.
PE Ratio―
PS Ratio3.37
PB Ratio-28.35
Price to Fair Value-28.35
Price to FCF-4.80
Price to Operating Cash Flow-4.88
PEG Ratio0.54
Income Statement
In the last 12 months, Ultragenyx Pharmaceutical had revenue of 673.00M and earned -575.00M in profits. Earnings per share was -5.83.
Revenue673.00M
Gross Profit564.00M
Operating Income-535.00M
Pretax Income-571.00M
Net Income-575.00M
EBITDA-500.00M
Earnings Per Share (EPS)-5.83
Cash Flow
In the last 12 months, operating cash flow was -466.00M and capital expenditures -6.00M, giving a free cash flow of -472.00M billion.
Operating Cash Flow-466.00M
Free Cash Flow-472.00M
Free Cash Flow per Share-4.89
Dividends & Yields
Ultragenyx Pharmaceutical pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.13
52-Week Price Change-44.83%
50-Day Moving Average26.01
200-Day Moving Average30.92
Relative Strength Index (RSI)43.91
Average Volume (3m)2.39M
Important Dates
Ultragenyx Pharmaceutical upcoming earnings date is Apr 30, 2026, TBA (Confirmed).
Last Earnings DateFeb 12, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Ultragenyx Pharmaceutical as a current ratio of 2.48, with Debt / Equity ratio of -1595.00%
Current Ratio2.48
Quick Ratio2.34
Debt to Market Cap0.55
Net Debt to EBITDA-1.68
Interest Coverage Ratio-8.63
Taxes
In the past 12 months, Ultragenyx Pharmaceutical has paid 4.00M in taxes.
Income Tax4.00M
Effective Tax Rate>-0.01
Enterprise Valuation
Ultragenyx Pharmaceutical EV to EBITDA ratio is -6.22, with an EV/FCF ratio of -6.59.
EV to Sales4.62
EV to EBITDA-6.22
EV to Free Cash Flow-6.59
EV to Operating Cash Flow-6.67
Balance Sheet
Ultragenyx Pharmaceutical has $693.00M in cash and marketable securities with $1.28B in debt, giving a net cash position of -$583.00M billion.
Cash & Marketable Securities$693.00M
Total Debt$1.28B
Net Cash-$583.00M
Net Cash Per Share-$6.04
Tangible Book Value Per Share-$2.97
Margins
Gross margin is 83.85%, with operating margin of -79.49%, and net profit margin of -85.44%.
Gross Margin83.85%
Operating Margin-79.49%
Pretax Margin-84.84%
Net Profit Margin-85.44%
EBITDA Margin-74.29%
EBIT Margin-79.49%
Analyst Forecast
The average price target for Ultragenyx Pharmaceutical is $53.35, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$53.35
Price Target Upside137.01% Upside
Analyst ConsensusStrong Buy
Analyst Count21
Revenue Growth Forecast20.63%
EPS Growth Forecast8.09%